A blood test conducted in a prehospital setting may rapidly distinguish between ischemic and hemorrhagic stroke, potentially facilitating more rapid, targeted treatment. The test measures the levels ...
PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...
University of Cincinnati researchers are presenting abstracts at the European Stroke Organization Conference (ESOC) 2023, May 24-26 in Munich, Germany, including the results of the first large-scale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results